|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Functional Variant rs4442975 Modulating FOXA1 Binding Affinity Can Influence Bone Marrow Suppression during Neoadjuvant Chemotherapy for Luminal A Type Breast Cancer.
|
30881995 |
2019 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ABC successfully identifies previously characterized functional SNVs, such as the rs4784227 breast cancer risk associated SNP that modulates the affinity of FOXA1 for the chromatin.
|
25995231 |
2015 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A new study shows that SNPs associated with breast cancer risk are located in enhancer regions and alter binding affinity for the pioneer factor FOXA1.
|
23104063 |
2012 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recently, the rs4442975 T-allele, which disrupts the recruitment of FOXA1 and interacts with the IGFBP5 promoter, was associated to BC susceptibility in a European population.
|
27835577 |
2016 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Biological assays indicated that the germline G>T variation at rs6506689 creates a FOXA1-binding site and up-regulates the expression of RAB31, thus playing an important role in the development of BC.
|
30182384 |
2018 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
NBCs less frequently harboured PIK3CA mutations than common forms of ER<sup>+</sup> /HER2<sup>-</sup> , luminal A and invasive lobular carcinomas (p < 0.05), and showed a significantly higher frequency of somatic mutations affecting ARID1A (17% versus 2%, p < 0.05) and the transcription factor-encoding genes FOXA1 (17% versus 2%, p = 0.01) and TBX3 (17% versus 3%, p < 0.05) than common-type ER<sup>+</sup> /HER2<sup>-</sup> breast carcinomas.
|
27925203 |
2017 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results show that breast cancer risk-associated SNPs are enriched in the cistromes of FOXA1 and ESR1 and the epigenome of histone H3 lysine 4 monomethylation (H3K4me1) in a cancer- and cell type-specific manner.
|
23001124 |
2012 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this resource paper, we present the genome-wide localization analysis of SRC-3 chromatin affinity sites in MCF-7 human breast cancer chromatin and compare the cis binding sites to global cartographies for ER and FoxA1.
|
20181721 |
2010 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ultrasound assisted gene and photodynamic synergistic therapy with multifunctional FOXA1-siRNA loaded porphyrin microbubbles for enhancing therapeutic efficacy for breast cancer.
|
29758547 |
2018 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A conserved PR binding element was identified in PR binding regions from both cell lines, but there were distinct patterns of enrichment of known cofactor binding motifs, with FOXA1 sites over-represented in breast cancer cell binding regions and NF1 and AP-1 motifs uniquely enriched in the immortalized normal line.
|
22545144 |
2012 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study explored the FOXA1 relationship with luminal and basal breast cancer subtypes, proliferation markers, and survival in breast cancer patients who had received similar treatment.
|
18037662 |
2008 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Stable expression of FOXA1, but not ERα, reduced the expression of <i>IL6</i> in the FOXA1- and ERα-negative breast cancer MDA-MB-231 cells and TAM-R cells, without affecting the activation of the NF-κB signaling pathways.
|
28270510 |
2017 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The analysis revealed already well-established associations with XBP1 and FOXA1, but also identified a strong association with CT62, a potential immunotherapeutic target with few previous associations with breast cancer.
|
30760519 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, a groundbreaking study by the Lupien group has shown that risk-associated SNPs of breast cancer are enriched for FOXA1 binding sites, which influences the function of this transcription factor.
|
23427833 |
2013 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Our results show that breast cancer risk-associated SNPs are enriched in the cistromes of FOXA1 and ESR1 and the epigenome of histone H3 lysine 4 monomethylation (H3K4me1) in a cancer- and cell type-specific manner.
|
23001124 |
2012 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interdependency between these three factors in breast cancer and normal mammary development has been suggested, but the specific role for FOXA1 is not known.
|
20501593 |
2010 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The comparison of our signature with two pioneering signatures, the Sorlie's signature and PAM50, suggests a novel marker, FOXA1, in breast cancer classification.
|
26404658 |
2015 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FOXA1, a known driver of hormone-receptor positive breast cancer, harbours a mutational hotspot in its promoter leading to overexpression through increased E2F binding.
|
28658208 |
2017 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FOXA1 immunoreactivity was significantly elevated in the relapse-free breast cancer patients treated with tamoxifen.
|
22476979 |
2012 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This is in line with other studies suggesting these SNPs as risk-associated polymorphisms which may lead to a change in the affinity of FOXA1, as a distal enhancer, to <i>TOX3</i> and thus change in <i>TOX3</i> expression, which can eventually affect the risk of breast cancer.
|
31338012 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here in this study, we aimed to identify which are the proteins that could potentially control FOXA1 function in breast cancer cell lines expressing different molecular markers.
|
30572598 |
2018 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.
|
31644911 |
2019 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In contrast, constitutive (MYC, TBX3) and signal-induced (TP53, FOXA1) DB-TFs that do not mediate default repression are directly altered in breast cancer.
|
28215225 |
2017 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FOXA1 knockdown in the epithelial breast cancer MCF7 cells reduced E-cadherin protein expression without decreasing its mRNA expression.
|
28867731 |
2017 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Particularly, our model correctly prioritized SNPs that are proved to be enriched for the binding sites of FOXA1 in breast cancer cell lines from previous studies.
|
28361702 |
2017 |